NASDAQ: TRAW
Traws Pharma Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their TRAW stock forecasts and price targets.

Forecast return on equity

Is TRAW forecast to generate an efficient return?

Company
-145.26%
Industry
18.59%
Market
333.94%
TRAW's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TRAW forecast to generate an efficient return on assets?

Company
-53.06%
Industry
13.15%
TRAW is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TRAW earnings per share forecast

What is TRAW's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$36.23-137.21%
Avg 2 year Forecast
-$0.83-100.85%

TRAW revenue forecast

What is TRAW's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$234.6k-91.76%
Avg 2 year Forecast
$306.0k-89.25%
TRAW's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TRAW revenue growth forecast

How is TRAW forecast to perform vs Biotechnology companies and vs the US market?

Company
-91.76%
Industry
10,214.33%
Market
1,467.21%
TRAW's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TRAW's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TRAW vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRAW$2.16N/AN/A
CVKD$8.27N/AN/A
ABP$6.49N/AN/A
HOTH$1.14$5.00+338.60%Strong Buy
LSTA$1.90$23.50+1,136.84%Strong Buy

Traws Pharma Stock Forecast FAQ

What is TRAW's earnings growth forecast for 2025-2026?

(NASDAQ: TRAW) Traws Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 213.18%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,977.87%.

Traws Pharma's earnings in 2025 is $93,350,000.On average, 3 Wall Street analysts forecast TRAW's earnings for 2025 to be -$289,512,308, with the lowest TRAW earnings forecast at -$278,158,884, and the highest TRAW earnings forecast at -$298,027,376.

In 2026, TRAW is forecast to generate -$6,602,054 in earnings, with the lowest earnings forecast at -$6,343,150 and the highest earnings forecast at -$6,796,232.

If you're new to stock investing, here's how to buy Traws Pharma stock.

What is TRAW's revenue growth forecast for 2025-2026?

(NASDAQ: TRAW) Traws Pharma's forecast annual revenue growth rate of -91.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 10,214.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,467.21%.

Traws Pharma's revenue in 2025 is $2,846,000.On average, 3 Wall Street analysts forecast TRAW's revenue for 2025 to be $1,874,657, with the lowest TRAW revenue forecast at $1,801,141, and the highest TRAW revenue forecast at $1,929,794.

In 2026, TRAW is forecast to generate $2,445,205 in revenue, with the lowest revenue forecast at $2,349,315 and the highest revenue forecast at $2,517,123.

What is TRAW's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: TRAW) forecast ROA is -53.06%, which is lower than the forecast US Biotechnology industry average of 13.15%.

What is TRAW's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: TRAW) Traws Pharma's current Earnings Per Share (EPS) is $97.38. On average, analysts forecast that TRAW's EPS will be -$36.23 for 2025, with the lowest EPS forecast at -$34.81, and the highest EPS forecast at -$37.30. In 2026, TRAW's EPS is forecast to hit -$0.83 (min: -$0.79, max: -$0.85).

What is TRAW's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: TRAW) forecast ROE is -145.26%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.